Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Cholestyramine is a bile acid binding resin with which it forms an insoluble complex that is excreted in the feces. It prevents the normal reabsorption of bile acids and forces the liver to produce more bile, thus reducing the body's cholesterol levels (especially LDL), since cholesterol is a major component of bile. Oral administration twice a day.
At the time of the last update, we found no published data on breastfeeding.
The intestinal absorption of the drug is null (AEMPS 2013, New Zealand Data Sheet 2010), so it cannot pass into breast milk, nor would it pass into the infant's plasma from ingested breast milk.
In addition, its high molecular weight makes it very unlikely to pass into breast milk in significant quantities.
Its prolonged use can cause plasma deficiency, due to lack of absorption, of fat-soluble vitamins (A, D, E, K), so it may be advisable to supplement to avoid deficiency of these vitamins in breast milk.
Several medical societies, experts and expert consensus consider safe the use of this medication during breastfeeding (Hale, LactMed, Lawrence 2016 p393, Serrano 2015, Briggs 2015, Heetun 2007, Mahadevan 2006).
It is advisable to follow a lipid-lowering diet and engage in regular physical activity daily, at least half an hour daily.
For considerations on the appropriateness of lipid-lowering treatment during breastfeeding see Maternal hyperlipidemia, hypercholesterolemia, hypertriglyceridemia.
See below the information of this related product: